Cargando…

Efficacy and Safety of Q10 Ubiquinol With Vitamins B and E in Neurodevelopmental Disorders: A Retrospective Chart Review

Increased oxidative stress and defective mitochondrial functioning are shared features among many brain disorders. The aim of this study was to verify retrospectively the clinical efficacy and safety of a metabolic support therapy with Q10 ubiquinol, vitamin E and complex-B vitamins in various neuro...

Descripción completa

Detalles Bibliográficos
Autores principales: Cucinotta, Francesca, Ricciardello, Arianna, Turriziani, Laura, Mancini, Arianna, Keller, Roberto, Sacco, Roberto, Persico, Antonio M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927903/
https://www.ncbi.nlm.nih.gov/pubmed/35308885
http://dx.doi.org/10.3389/fpsyt.2022.829516
_version_ 1784670544001499136
author Cucinotta, Francesca
Ricciardello, Arianna
Turriziani, Laura
Mancini, Arianna
Keller, Roberto
Sacco, Roberto
Persico, Antonio M.
author_facet Cucinotta, Francesca
Ricciardello, Arianna
Turriziani, Laura
Mancini, Arianna
Keller, Roberto
Sacco, Roberto
Persico, Antonio M.
author_sort Cucinotta, Francesca
collection PubMed
description Increased oxidative stress and defective mitochondrial functioning are shared features among many brain disorders. The aim of this study was to verify retrospectively the clinical efficacy and safety of a metabolic support therapy with Q10 ubiquinol, vitamin E and complex-B vitamins in various neurodevelopmental disorders. This retrospective chart review study included 59 patients (mean age 10.1 ± 1.2 y.o., range 2.5–39 years; M:F = 2.47:1), diagnosed with Autism Spectrum Disorder (n = 17), Autism Spectrum Disorder with co-morbid Intellectual Disability (n = 19), Intellectual Disability or Global Developmental Delay (n = 15), Attention-Deficit/Hyperactivity Disorder (n = 3) and Intellectual Disability in Phelan-McDermid syndrome due to chr. 22q13.33 deletion (n = 5). After a minimum of 3 months of therapy, a positive outcome was recorded in 45/59 (76.27%) patients, with Clinical Global Impression—Improvement scores ranging between 1 (“very much improved”) and 3 (“minimally improved”). The most widespread improvements were recorded in cognition (n = 26, 44.1%), adaptative functioning (n = 26, 44.1%) and social motivation (n = 19, 32.2%). Improvement rates differed by diagnosis, being observed most consistently in Phelan-McDermid Syndrome (5/5, 100%), followed by Intellectual Disability/Global Developmental Delay (13/15, 86.7%), Autism Spectrum Disorder with co-morbid Intellectual Disability (15/19, 78.9%), Autism Spectrum Disorder (11/17, 64.7%) and ADHD (1/3, 33.3%). No significant adverse event or side effect leading to treatment discontinuation were recorded. Mild side effects were reported in 18 (30.5%) patients, with the most frequent being increased hyperactivity (9/59, 15.3%). This retrospective chart review suggests that metabolic support therapy with Q10 ubiquinol, vitamin E and complex-B vitamins is well tolerated and produces some improvement in the majority of patients with neurodevelopmental disorders, especially in the presence of intellectual disability. Randomized controlled trials for each single neurodevelopmental disorder are now warranted to conclusively demonstrate the efficacy of these mitochondrial bioenergetic and antioxidant agents and to estimate their therapeutic effect size.
format Online
Article
Text
id pubmed-8927903
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89279032022-03-18 Efficacy and Safety of Q10 Ubiquinol With Vitamins B and E in Neurodevelopmental Disorders: A Retrospective Chart Review Cucinotta, Francesca Ricciardello, Arianna Turriziani, Laura Mancini, Arianna Keller, Roberto Sacco, Roberto Persico, Antonio M. Front Psychiatry Psychiatry Increased oxidative stress and defective mitochondrial functioning are shared features among many brain disorders. The aim of this study was to verify retrospectively the clinical efficacy and safety of a metabolic support therapy with Q10 ubiquinol, vitamin E and complex-B vitamins in various neurodevelopmental disorders. This retrospective chart review study included 59 patients (mean age 10.1 ± 1.2 y.o., range 2.5–39 years; M:F = 2.47:1), diagnosed with Autism Spectrum Disorder (n = 17), Autism Spectrum Disorder with co-morbid Intellectual Disability (n = 19), Intellectual Disability or Global Developmental Delay (n = 15), Attention-Deficit/Hyperactivity Disorder (n = 3) and Intellectual Disability in Phelan-McDermid syndrome due to chr. 22q13.33 deletion (n = 5). After a minimum of 3 months of therapy, a positive outcome was recorded in 45/59 (76.27%) patients, with Clinical Global Impression—Improvement scores ranging between 1 (“very much improved”) and 3 (“minimally improved”). The most widespread improvements were recorded in cognition (n = 26, 44.1%), adaptative functioning (n = 26, 44.1%) and social motivation (n = 19, 32.2%). Improvement rates differed by diagnosis, being observed most consistently in Phelan-McDermid Syndrome (5/5, 100%), followed by Intellectual Disability/Global Developmental Delay (13/15, 86.7%), Autism Spectrum Disorder with co-morbid Intellectual Disability (15/19, 78.9%), Autism Spectrum Disorder (11/17, 64.7%) and ADHD (1/3, 33.3%). No significant adverse event or side effect leading to treatment discontinuation were recorded. Mild side effects were reported in 18 (30.5%) patients, with the most frequent being increased hyperactivity (9/59, 15.3%). This retrospective chart review suggests that metabolic support therapy with Q10 ubiquinol, vitamin E and complex-B vitamins is well tolerated and produces some improvement in the majority of patients with neurodevelopmental disorders, especially in the presence of intellectual disability. Randomized controlled trials for each single neurodevelopmental disorder are now warranted to conclusively demonstrate the efficacy of these mitochondrial bioenergetic and antioxidant agents and to estimate their therapeutic effect size. Frontiers Media S.A. 2022-03-03 /pmc/articles/PMC8927903/ /pubmed/35308885 http://dx.doi.org/10.3389/fpsyt.2022.829516 Text en Copyright © 2022 Cucinotta, Ricciardello, Turriziani, Mancini, Keller, Sacco and Persico. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Psychiatry
Cucinotta, Francesca
Ricciardello, Arianna
Turriziani, Laura
Mancini, Arianna
Keller, Roberto
Sacco, Roberto
Persico, Antonio M.
Efficacy and Safety of Q10 Ubiquinol With Vitamins B and E in Neurodevelopmental Disorders: A Retrospective Chart Review
title Efficacy and Safety of Q10 Ubiquinol With Vitamins B and E in Neurodevelopmental Disorders: A Retrospective Chart Review
title_full Efficacy and Safety of Q10 Ubiquinol With Vitamins B and E in Neurodevelopmental Disorders: A Retrospective Chart Review
title_fullStr Efficacy and Safety of Q10 Ubiquinol With Vitamins B and E in Neurodevelopmental Disorders: A Retrospective Chart Review
title_full_unstemmed Efficacy and Safety of Q10 Ubiquinol With Vitamins B and E in Neurodevelopmental Disorders: A Retrospective Chart Review
title_short Efficacy and Safety of Q10 Ubiquinol With Vitamins B and E in Neurodevelopmental Disorders: A Retrospective Chart Review
title_sort efficacy and safety of q10 ubiquinol with vitamins b and e in neurodevelopmental disorders: a retrospective chart review
topic Psychiatry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927903/
https://www.ncbi.nlm.nih.gov/pubmed/35308885
http://dx.doi.org/10.3389/fpsyt.2022.829516
work_keys_str_mv AT cucinottafrancesca efficacyandsafetyofq10ubiquinolwithvitaminsbandeinneurodevelopmentaldisordersaretrospectivechartreview
AT ricciardelloarianna efficacyandsafetyofq10ubiquinolwithvitaminsbandeinneurodevelopmentaldisordersaretrospectivechartreview
AT turrizianilaura efficacyandsafetyofq10ubiquinolwithvitaminsbandeinneurodevelopmentaldisordersaretrospectivechartreview
AT manciniarianna efficacyandsafetyofq10ubiquinolwithvitaminsbandeinneurodevelopmentaldisordersaretrospectivechartreview
AT kellerroberto efficacyandsafetyofq10ubiquinolwithvitaminsbandeinneurodevelopmentaldisordersaretrospectivechartreview
AT saccoroberto efficacyandsafetyofq10ubiquinolwithvitaminsbandeinneurodevelopmentaldisordersaretrospectivechartreview
AT persicoantoniom efficacyandsafetyofq10ubiquinolwithvitaminsbandeinneurodevelopmentaldisordersaretrospectivechartreview